Literature DB >> 34057471

Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult.

Julie Boyer1, Cristina Birzu1, Franck Bielle2, Clara Goulas3, Julien Savatovsky4, Carine Karachi5, Ahmed Idbaih1.   

Abstract

Entities:  

Keywords:  zzm321990 NTRK fusion; glioneuronal tumor; molecular targeted therapy

Mesh：

Substances：

Year:  2021        PMID： 34057471      PMCID： PMC8248836          DOI： 10.1093/neuonc/noab080

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  6 in total

1.  Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Authors:  Rolf W Sparidans; Yaogeng Wang; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-10-30       Impact factor: 3.205

2.  High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.

Authors:  Kazuhiko Kurozumi; Yoshiko Nakano; Joji Ishida; Takehiro Tanaka; Masatomo Doi; Junko Hirato; Akihiko Yoshida; Kana Washio; Akira Shimada; Takashi Kohno; Koichi Ichimura; Hiroyuki Yanai; Isao Date
Journal:  Brain Tumor Pathol       Date:  2019-04-22       Impact factor: 3.298

3.  Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.

Authors:  Christopher Alvarez-Breckenridge; Julie J Miller; Tracy T Batchelor; A John Iafrate; Priscilla K Brastianos; Naema Nayyar; Corey M Gill; Andrew Kaneb; Megan D'Andrea; Long P Le; Jesse Lee; Ju Cheng; Zongli Zheng; William E Butler; Pratik Multani; Edna Chow Maneval; Sun Ha Paek; Brian D Toyota; Dora Dias-Santagata; Sandro Santagata; Javier Romero; Alice T Shaw; Anna F Farago; Stephen Yip; Daniel P Cahill
Journal:  NPJ Precis Oncol       Date:  2017-03-20

4.  Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.

Authors:  Holger Fischer; Mohammed Ullah; Cecile C de la Cruz; Thomas Hunsaker; Claudia Senn; Thomas Wirz; Björn Wagner; Dragomir Draganov; Faye Vazvaei; Massimiliano Donzelli; Axel Paehler; Mark Merchant; Li Yu
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

5.  Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib.

Authors:  Musa Alharbi; Nahla Ali Mobark; Ali Abdullah O Balbaid; Fatmah A Alanazi; Wael Abdel Rahman Aljabarat; Eman A Bakhsh; Shakti H Ramkissoon; Malak Abedalthagafi
Journal:  JCO Precis Oncol       Date:  2020-06-30

Review 6.  NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target.

Authors:  Alessandro Gambella; Rebecca Senetta; Giammarco Collemi; Stefano Gabriele Vallero; Matteo Monticelli; Fabio Cofano; Pietro Zeppa; Diego Garbossa; Alessia Pellerino; Roberta Rudà; Riccardo Soffietti; Franca Fagioli; Mauro Papotti; Paola Cassoni; Luca Bertero
Journal:  Int J Mol Sci       Date:  2020-01-23       Impact factor: 5.923
  6 in total
  2 in total

Review 1.  NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives.

Authors:  Victoria Casado-Medrano; Alison O'Neill; Stephen Halada; Theodore W Laetsch; Andrew J Bauer; Aime T Franco
Journal:  Cancer Genet       Date:  2022-03-06

Review 2.  Innovating Strategies and Tailored Approaches in Neuro-Oncology.

Authors:  Alberto Picca; David Guyon; Orazio Santo Santonocito; Capucine Baldini; Ahmed Idbaih; Alexandre Carpentier; Antonio Giuseppe Naccarato; Mario Caccese; Giuseppe Lombardi; Anna Luisa Di Stefano
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.